Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 58 across all filing types
Latest filing 2026-01-16 Regulatory Filings
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
有価証券届出書（組込方式）
Regulatory Filings Classification · 97% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by Delta-Fly Pharma, Inc. It details the issuance of new share acquisition rights (第11回新株予約権). This type of document is a formal regulatory filing required for capital raising activities in Japan. Since it is a primary registration document for a securities offering rather than a simple announcement or a periodic financial report, it falls under the 'Regulatory Filings' category as the most appropriate classification for this specific type of Japanese financial disclosure.
2026-01-16 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's interim report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim report. H1 16
2025-11-14 Japanese
半期報告書－第16期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Delta-Fly Pharma, Inc. with the Kanto Local Finance Bureau on November 14, 2025. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-14 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) in the header and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related Cabinet Office Ordinance because resolutions were passed at the Annual General Meeting (AGM) held on June 26, 2025. Section 2 details the resolutions passed, including changes to the Articles of Incorporation and the election of directors and an alternate auditor. This structure—reporting the results of a shareholder meeting—is characteristic of a filing that reports the outcome of an AGM or EGM. Since the document reports the official results of shareholder votes (including vote counts and outcomes for each resolution), the most specific classification is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM, the content is the formal declaration of the voting results, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2025-06-27 Japanese
内部統制報告書－第15期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項). It details the scope, criteria, procedures, and conclusion regarding the assessment of internal controls over financial reporting (財務報告に係る内部統制). This structure and content strongly align with the requirements for an Audit Report or specific internal control assessment, which falls under the 'Audit Report / Information' category (AR) as defined, especially since it is not the full Annual Report (10-K) but a specific control assessment document. Reviewing the definitions: - 10-K: Official yearly report covering company activity and full financial performance. (This is a specific control report, not the full 10-K). - AR: Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports). This fits the description of a standalone internal control assessment report. Therefore, the classification is AR.
2025-06-27 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (614 characters) and contains a header section typical of Japanese regulatory filings, specifically mentioning a '確認書' (Confirmation Document) submitted to the '関東財務局長' (Kanto Local Finance Bureau Director) based on Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. Section 1 explicitly states that the Representative Director and CFO confirm the appropriateness of the contents of the company's '有価証券報告書' (Securities Report) for the 15th fiscal period (ending March 31, 2025). This document is a confirmation/attestation regarding the accuracy of a primary filing (likely a 10-K equivalent in Japan, which is the Annual Securities Report). Since this is a short confirmation document related to the annual filing, and not the full Annual Report (10-K) or a general Audit Report (AR), it fits best under the general category for regulatory filings that don't have a more specific code, or potentially as a supporting document for the Annual Report process. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific confirmation document that isn't the main report itself, although it is closely related to the 10-K process. However, since it is a confirmation of the *Securities Report* (which is the Japanese equivalent of the 10-K), and it is a standalone confirmation document, it is not the 10-K itself. It is a specific regulatory confirmation. Given the limited options, RNS (Regulatory Filings) is the best fit for a specific, short regulatory confirmation document that isn't a standard report type like 10-K or IR. FY 2025
2025-06-27 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.